Literature DB >> 7864177

Soluble TNF binding proteins modulate the negative inotropic properties of TNF-alpha in vitro.

S Kapadia1, G Torre-Amione, T Yokoyama, D L Mann.   

Abstract

Soluble tumor necrosis factor (TNF) binding proteins (TNF-BPs) were characterized with respect to their capacity to modulate the negative inotropic properties of TNF-alpha in isolated contracting cardiac myocytes. Three TNF-BPs were evaluated: two natural monomeric human TNF monomeric binding proteins, TNF-BP1 and TNF-BP2, and sTNFR:Fc, a dimer of two molecules of human TNF-BP2 linked by the Fc portion of the human immunoglobulin G1 molecule. When TNF-alpha (25 pM) was allowed to form TNF-BP-TNF-alpha complexes, the negative inotropic effects of TNF-alpha were completely prevented by "neutralizing concentrations" of TNF-BPs, whereas lesser concentrations of TNF-BPs only partially attenuated the negative inotropic effects of TNF-alpha. The dimeric binding protein sTNFR:Fc was more effective on a molar basis than either of the monomeric binding proteins (TNF-BP1 or TNF-BP2) with respect to blocking the negative inotropic effects of TNF-alpha. When cardiac myocytes that had been treated with TNF-alpha (25 pM) were exposed to neutralizing concentrations of TNF-BP1, TNF-BP2, and sTNFR:Fc, the negative inotropic effects were completely reversed within 30 min. Thus these studies show for the first time that TNF-BPs are sufficient to prevent, as well as reverse, the negative inotropic properties of TNF-alpha in vitro.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7864177     DOI: 10.1152/ajpheart.1995.268.2.H517

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  23 in total

Review 1.  Clinical implications of tumour necrosis factor alpha antagonism in patients with congestive heart failure.

Authors:  G Torre-Amione; S S Stetson; J A Farmer
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 2.  The role of anti-cytokine therapy in the failing heart.

Authors:  A Deswal; A Misra; B Bozkurt
Journal:  Heart Fail Rev       Date:  2001-03       Impact factor: 4.214

3.  Are cardiovascular diseases a subspeciality of clinical immunology?

Authors:  Pier Luigi Meroni; Piersandro Riboldi
Journal:  Clin Rev Allergy Immunol       Date:  2002-12       Impact factor: 8.667

Review 4.  Is too much neurohormonal blockade harmful?

Authors:  Inder S Anand
Journal:  Curr Cardiol Rep       Date:  2004-05       Impact factor: 2.931

5.  CXCR4 modulates contractility in adult cardiac myocytes.

Authors:  Robert T Pyo; Jinliang Sui; Ashwini Dhume; Julieta Palomeque; Burns C Blaxall; George Diaz; James Tunstead; Diomedes E Logothetis; Roger J Hajjar; Alison D Schecter
Journal:  J Mol Cell Cardiol       Date:  2006-09-28       Impact factor: 5.000

6.  Cardiovascular dysfunction in burns: review of the literature.

Authors:  G S Abu-Sittah; K A Sarhane; S A Dibo; A Ibrahim
Journal:  Ann Burns Fire Disasters       Date:  2012-03-31

Review 7.  Chronic heart failure and the immune system.

Authors:  Daniela Mari; Federica Di Berardino; Massimo Cugno
Journal:  Clin Rev Allergy Immunol       Date:  2002-12       Impact factor: 8.667

8.  Effect of the soluble TNF-antagonist etanercept on tumor necrosis factor bioactivity and stability.

Authors:  Douglas L Mann; Biykem Bozkurt; Guillermo Torre-Amione; Ozlem Z Soran; Natarajan Sivasubramanian
Journal:  Clin Transl Sci       Date:  2008-09       Impact factor: 4.689

9.  Myocardial Fas and cytokine expression in end-stage heart failure: impact of LVAD support.

Authors:  Maninder S Bedi; Rene J Alvarez; Toru Kubota; Richard Sheppard; Robert L Kormos; Michael P Siegenthaler; Arthur M Feldman; Charles F McTiernan; Dennis M McNamara
Journal:  Clin Transl Sci       Date:  2008-12       Impact factor: 4.689

10.  Tumour necrosis factor receptor 1 and mortality in a multi-ethnic cohort: the Northern Manhattan Study.

Authors:  Jorge M Luna; Yeseon Moon; Khin Liu; Steven Spitalnik; Myunghee Paik; Ralph Sacco; Mitchell S V Elkind
Journal:  Age Ageing       Date:  2013-01-15       Impact factor: 10.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.